Naxitamab (brand name Danyelza®) is a humanized monoclonal antibody that targets GD2 (disialoganglioside GD2), a glycolipid antigen highly expressed on neuroblastoma cells and some other solid tumors (e.g., osteosarcoma, melanoma). It is an IgG1 isotype engineered to enhance antibody-dependent cellular cytotoxicity (ADCC). By binding to GD2, naxitamab directs immune cells (primarily natural killer cells and macrophages) to attack GD2-positive tumor cells. It is approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.